Evogene Targets Acute Graft-Versus-Host Disease in AI-Driven Drug Discovery Program
Bitget2026/10/28 12:30- Evogene announced acute graft-versus-host disease as the target for its internal AI-driven drug discovery program, focusing on patients unresponsive to steroids.
- Reported discovery-stage findings showed promising potency, selectivity and safety-related profiles; lead candidates are advancing toward studies supporting an investigational new drug application.
- The program targets a potential multibillion-dollar market where ruxolitinib remains the only approved second-line therapy.
- The disease affects approximately 30%-40% of stem cell transplant recipients; mortality among steroid-refractory patients can reach 50%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
